PARK16 - Parkinson's Disease Locus 16

📖 Wiki Page

gene1225 wordssynced 2026-04-02

PARK16 Gene

...

PARK16 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">PARK16 - Parkinson's Disease Locus 16</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>RAB7L1 (primary gene at locus)</td>
</tr>
<tr>
<td class="label">Alternative Names</td>
<td>RAB7B, Rab7-like protein 1</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>RAB7-like 1</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>1q32.1</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>493856</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000109189</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q96NA5</td>
</tr>
<tr>
<td class="label">Locus</td>
<td>PARK16 (1q32)</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>Function</td>
</tr>
<tr>
<td class="label">RAB7L1</td>
<td>Rab GTPase, vesicular trafficking</td>
</tr>
<tr>
<td class="label">SLC45A3</td>
<td>Solute carrier, prostate-specific</td>
</tr>
<tr>
<td class="label">NUCKS1</td>
<td>Nuclear casein kinase substrate</td>
</tr>
<tr>
<td class="label">PM20D1</td>
<td>Peptidase/amino acid metabolism</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cortex</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Testis</td>
<td>High</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Liver</td>
<td>Low-Moderate</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Role of RAB7L1</td>
</tr>
<tr>
<td class="label">Lysosomal function</td>
<td>Maintains lysosomal homeostasis</td>
</tr>
<tr>
<td class="label">Autophagy</td>
<td>Required for autophagosome formation</td>
</tr>
<tr>
<td class="label">Protein sorting</td>
<td>Coordinates intracellular trafficking</td>
</tr>
<tr>
<td class="label">Lipid metabolism</td>
<td>Regulates lipid trafficking</td>
</tr>
<tr>
<td class="label">LRRK2 interaction</td>
<td>Genetic/functional interaction</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/parkinson" style="color:#ef9a9a">Parkinson</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">10 edges</a></td>
</tr>
</table>

Introduction

PARK16 (Parkinson's Disease Locus 16) was first identified as a significant genetic risk factor for [Parkinson's disease](/diseases/parkinsons-disease) in a genome-wide association study (GWAS) meta-analysis published in 2010. [@satake2009] This locus on chromosome 1q32 spans approximately 200 kb and contains multiple genes, of which RAB7L1 (Rab7-like 1) has emerged as the primary effector gene mediating PD risk. The locus represents one of the most robust and consistently replicated PD risk loci discovered through GWAS.

The identification of PARK16 provided important insights into the pathogenesis of PD, highlighting the role of lysosomal trafficking, autophagy, and protein homeostasis in dopaminergic neuron survival. Subsequent research has demonstrated that RAB7L1 interacts genetically and functionally with [LRRK2](/genes/lrrk2), another major PD risk gene, providing a mechanistic link between two important PD pathways. [@takanashi2013]

Gene Overview

Genes at the PARK16 Locus

The PARK16 locus contains multiple genes:

RAB7L1 is considered the primary effector gene due to its brain expression and functional studies.

Protein Structure and Function

RAB7L1 Protein

RAB7L1 is a ~220 amino acid protein belonging to the Rab GTPase family:

Structural Features

Rab GTPase domain: Core catalytic domain (~200 aa)
GTP/GDP binding motifs: Switch I and II regions
C-terminal prenylation site: CAAX motif for membrane localization
Hypervariable region: Target specificity determinants

GTase Cycle
Like other Rab proteins, RAB7L1 cycles between active (GTP-bound) and inactive (GDP-bound) states:

GDP-bound state: Cytosolic, inactive
GTP-bound state: Membrane-associated, active
GDI displacement: GDP dissociation inhibitor
GEF activation: Guanine nucleotide exchange factor

Molecular Functions

Vesicular Trafficking

Regulates trafficking between Golgi and endosomes
Controls late endosomal/lysosomal pathway
Coordinates endocytic and secretory pathways
Maintains retromer complex function

Autophagy Regulation

Essential for autophagosome formation
Coordinates autophagosome-lysosome fusion
Modulates lysosomal function
Controls protein clearance pathways [@kuwahara2022]

Lysosomal Function

Maintains lysosomal homeostasis
Regulates lysosomal membrane dynamics
Coordinates lipid trafficking
Supports lysosomal degradation capacity

Expression Pattern

Cellular Localization

Golgi apparatus: Primary localization
Endosomes: Dynamic localization
Lysosomes: Upon activation
Cytosol: Inactive pool

Normal Physiological Function

Neuronal Functions

Protein Homeostasis

Maintains neuronal protein quality control
Coordinates synthesis, trafficking, and degradation
Prevents accumulation of misfolded proteins
Supports dendritic and axonal trafficking

Autophagy-Lysosome Pathway

RAB7L1 is essential for autophagosome formation
Coordinates maturation and fusion with lysosomes
Maintains cellular clearance capacity
Prevents toxic protein aggregation

Lysosomal Function

Regulates lysosomal pH and enzyme activity
Controls lysosomal membrane dynamics
Coordinates lipid and protein trafficking
Maintains neuronal metabolic homeostasis

Cell-Type Specific Functions

Dopaminergic Neurons

Particularly vulnerable to RAB7L1 dysfunction
Supports survival in substantia nigra
Coordinates protein clearance in long axons
Maintains synaptic vesicle dynamics

Other Neurons

Supports general neuronal protein homeostasis
Important for dendritic arbor maintenance
Modulates axonal transport

Disease Associations

Parkinson's Disease

PARK16 is one of the most significant PD risk loci:

Genetic Association

GWAS-identified variant: rs823118 (RAB7L1)
Odds ratio: ~1.3-1.5 per risk allele
Population-specific effects observed
Consistent replication across cohorts [@international2011]

Mechanistic Pathways

LRRK2 Interaction
RAB7L1 directly interacts with [LRRK2](/genes/lrrk2), the most common genetic cause of PD:

LRRK2 phosphorylates RAB7L1
RAB7L1 modulates LRRK2 activity
Combined dysfunction accelerates neurodegeneration [@macleod2013]
May explain synergistic genetic effects

Mechanisms of Neurodegeneration

Impaired Protein Clearance

Autophagy-lysosomal pathway dysfunction
Accumulation of [α-synuclein](/proteins/alpha-synuclein) aggregates
Impaired clearance of damaged proteins
Endoplasmic reticulum stress

Lysosomal Dysfunction

Reduced lysosomal degradative capacity
Altered lysosomal pH and enzyme activity
Lipid accumulation in neurons
Impaired cellular clearance

Dopaminergic Neuron Vulnerability

Age-dependent degeneration
Axonal maintenance deficits
Synaptic dysfunction
Mitochondrial stress

Other Neurological Associations

Essential tremor: Some association reported
Alzheimer's disease: Possible interaction with amyloid pathology
Aging: Age-dependent RAB7L1 dysfunction

Signaling and Interaction Network

Mermaid diagram (expand to render)

Therapeutic Implications

Drug Development

RAB7L1-Targeted Approaches

Small molecule activators: Enhance RAB7L1 function
Gene therapy: Viral vector-mediated expression
Protein replacement: Direct protein delivery

Combination Strategies

LRRK2 inhibitors: May benefit PARK16 carriers
Autophagy enhancers: Compensate for RAB7L1 dysfunction
Lysosomal modulators: Improve clearance capacity

Challenges

Protein targeting: Achieving proper cellular localization

GTPase modulation: Developing selective RAB7L1 modulators

Blood-brain barrier: CNS penetration requirements

Timing: Intervention at appropriate disease stage

Biomarker Potential

RAB7L1 expression as PD progression marker
Genetic testing for PARK16 risk variants
Lysosomal function assays
Autophagy biomarkers

Research Directions

Current Areas of Investigation

Gene therapy: AAV-mediated RAB7L1 delivery in models

Small molecule modulators: RAB7L1 activity enhancers

iPSC models: Patient-derived dopaminergic neurons

Biomarkers: RAB7L1-related biomarkers

Combination therapy: Synergy with LRRK2 inhibitors

Key Unanswered Questions

What is the precise molecular mechanism of RAB7L1 dysfunction in PD?
Can RAB7L1 modulation slow or reverse neurodegeneration?
What is the optimal timing for intervention?
How does RAB7L1 interact with other PD risk genes?

References

[Satake et al., GWAS identifies PARK16 as PD risk factor (2009)](https://pubmed.ncbi.nlm.nih.gov/19915576/)

[Takanashi et al., RAB7L1 interacts with LRRK2 (2013)](https://pubmed.ncbi.nlm.nih.gov/23376214/)

[MacLeod et al., RAB7L1-LRRK2 interaction in PD (2013)](https://pubmed.ncbi.nlm.nih.gov/23475836/)

[Kuwahara et al., Lysosomal lipid signaling in PD (2022)](https://pubmed.ncbi.nlm.nih.gov/35418567/)

[Zeng et al., RAB7L1-mediated trafficking in PD (2024)](https://pubmed.ncbi.nlm.nih.gov/37646892/)

[International PD Genetics Consortium, Imputation of rare variants (2011)](https://pubmed.ncbi.nlm.nih.gov/21738492/)

[Choi et al., RAB7L1 deficiency leads to dopaminergic neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/33242419/)

[Beilina et al., RAB7L1 as LRRK2 activity modifier (2020)](https://pubmed.ncbi.nlm.nih.gov/32029560/)

[Usenko et al., Lysosomal dysfunction in PARK16 PD (2023)](https://pubmed.ncbi.nlm.nih.gov/37353421/)

[Xie et al., RAB7L1 in neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35686189/)

Pathway Diagram

The following diagram shows the key molecular relationships involving PARK16 - Parkinson's Disease Locus 16 discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

PARK16 - Parkinson's Disease Locus 16

PARK16 Gene

PARK16 Gene

Introduction

Gene Overview

Genes at the PARK16 Locus

Protein Structure and Function

RAB7L1 Protein

Molecular Functions

Expression Pattern

Cellular Localization

Normal Physiological Function

Neuronal Functions

Cell-Type Specific Functions

Disease Associations

Parkinson's Disease

Mechanisms of Neurodegeneration

Other Neurological Associations

Signaling and Interaction Network

Therapeutic Implications

Drug Development

Challenges

Biomarker Potential

Research Directions

Current Areas of Investigation

Key Unanswered Questions

See Also

References

Pathway Diagram